O	0	6	Effect
O	7	9	of
B-intervention	10	20	everolimus
O	21	23	on
O	24	28	bone
O	29	35	marker
O	36	42	levels
O	43	46	and
O	47	58	progressive
O	59	66	disease
O	67	69	in
O	70	74	bone
O	75	77	in
O	78	84	BOLERO
O	84	85	-
O	85	86	2
O	86	87	.

O	88	94	Breast
O	95	101	Cancer
O	102	108	Trials
O	109	111	of
O	112	116	Oral
O	117	127	Everolimus
O	128	129	2
O	130	131	(
O	131	137	BOLERO
O	137	138	-
O	138	139	2
O	139	140	)
O	140	141	,
O	142	143	a
O	144	149	phase
O	150	153	III
O	154	159	study
O	160	162	in
B-eligibility	163	177	postmenopausal
I-eligibility	178	183	women
I-eligibility	184	188	with
I-eligibility	189	197	estrogen
I-eligibility	198	206	receptor
I-eligibility	206	207	-
I-eligibility	207	215	positive
I-eligibility	216	222	breast
I-eligibility	223	229	cancer
I-eligibility	230	241	progressing
I-eligibility	242	249	despite
I-eligibility	250	262	nonsteroidal
I-eligibility	263	272	aromatase
I-eligibility	273	282	inhibitor
I-eligibility	283	290	therapy
O	290	291	,
O	292	298	showed
O	299	312	statistically
O	313	324	significant
O	325	333	benefits
O	334	338	with
O	339	345	adding
O	346	356	everolimus
O	357	359	to
O	360	370	exemestane
O	370	371	.

O	372	380	Moreover
O	380	381	,
O	382	384	in
O	385	396	preclinical
O	397	404	studies
O	404	405	,
O	406	415	mammalian
O	416	422	target
O	423	425	of
O	426	435	rapamycin
O	436	446	inhibition
O	447	450	was
O	451	461	associated
O	462	466	with
O	467	476	decreased
O	477	487	osteoclast
O	488	496	survival
O	497	500	and
O	501	509	activity
O	509	510	.

O	511	522	Exploratory
O	523	531	analyses
O	532	534	in
O	535	541	BOLERO
O	541	542	-
O	542	543	2
O	544	553	evaluated
O	554	557	the
O	558	564	effect
O	565	567	of
O	568	578	everolimus
O	579	581	on
O	582	586	bone
O	587	593	marker
O	594	600	levels
O	601	604	and
O	605	616	progressive
O	617	624	disease
O	625	627	in
O	628	632	bone
O	632	633	.

O	634	642	Patients
O	643	647	were
O	648	655	treated
O	656	660	with
O	661	671	exemestane
O	672	673	(
O	673	677	25mg
O	677	678	/
O	678	681	day
O	681	682	)
O	683	686	and
O	687	697	randomized
O	698	699	(
O	699	700	2
O	700	701	:
O	701	702	1
O	702	703	)
O	704	706	to
O	707	717	everolimus
O	718	719	(
O	719	723	10mg
O	723	724	/
O	724	727	day
O	727	728	;
O	729	740	combination
O	740	741	)
O	742	744	or
B-control	745	752	placebo
I-control	753	754	(
I-control	754	764	exemestane
I-control	765	769	only
I-control	769	770	)
O	770	771	.

O	772	783	Exploratory
O	784	793	endpoints
O	794	802	included
B-outcome-Measure	803	810	changes
I-outcome-Measure	811	813	in
I-outcome-Measure	814	818	bone
I-outcome-Measure	819	827	turnover
I-outcome-Measure	828	834	marker
I-outcome-Measure	835	841	levels
O	842	844	vs
B-outcome-Measure	845	853	baseline
I-outcome-Measure	854	857	and
I-outcome-Measure	858	869	progressive
I-outcome-Measure	870	877	disease
I-outcome-Measure	878	880	in
I-outcome-Measure	881	885	bone
O	885	886	,
O	887	894	defined
O	895	897	as
O	898	909	unequivocal
O	910	921	progression
O	922	924	of
O	925	926	a
O	927	938	preexisting
O	939	943	bone
O	944	950	lesion
O	951	953	or
O	954	957	the
O	958	968	appearance
O	969	971	of
O	972	973	a
O	974	977	new
O	978	982	bone
O	983	989	lesion
O	989	990	.

B-outcome	991	999	Baseline
I-outcome	1000	1007	disease
I-outcome	1008	1023	characteristics
O	1024	1028	were
O	1029	1033	well
O	1034	1042	balanced
O	1043	1050	between
O	1051	1055	arms
O	1056	1057	(
O	1057	1058	N
O	1059	1060	=
B-total-participants	1061	1064	724
O	1064	1065	)
O	1065	1066	;
O	1067	1075	baseline
O	1076	1090	bisphosphonate
O	1091	1094	use
O	1095	1098	was
O	1099	1102	not
O	1103	1104	(
B-iv-bin-percent	1104	1106	43
I-iv-bin-percent	1106	1107	.
I-iv-bin-percent	1107	1108	9
I-iv-bin-percent	1108	1109	%
O	1110	1121	combination
O	1122	1124	vs
B-cv-bin-percent	1125	1127	54
I-cv-bin-percent	1127	1128	.
I-cv-bin-percent	1128	1129	0
I-cv-bin-percent	1129	1130	%
O	1131	1141	exemestane
O	1142	1146	only
O	1146	1147	)
O	1147	1148	.

O	1149	1151	At
O	1152	1153	a
O	1154	1160	median
O	1161	1163	of
O	1164	1166	18
O	1167	1173	months
O	1174	1176	of
O	1177	1183	follow
O	1183	1184	-
O	1184	1186	up
O	1186	1187	,
O	1188	1194	median
B-outcome	1195	1206	progression
I-outcome	1206	1207	-
I-outcome	1207	1211	free
I-outcome	1212	1220	survival
O	1221	1222	(
O	1222	1229	primary
O	1230	1238	endpoint
O	1238	1239	)
O	1240	1243	was
O	1244	1257	statistically
O	1258	1271	significantly
O	1272	1278	longer
O	1279	1283	with
O	1284	1287	the
O	1288	1299	combination
O	1300	1302	vs
O	1303	1313	exemestane
O	1314	1318	only
O	1319	1320	(
O	1320	1323	Cox
O	1324	1336	proportional
O	1337	1343	hazard
O	1344	1349	ratio
O	1350	1351	=
O	1352	1353	0
O	1353	1354	.
O	1354	1356	45
O	1356	1357	,
O	1358	1360	95
O	1360	1361	%
O	1362	1372	confidence
O	1373	1381	interval
O	1382	1383	=
O	1384	1385	0
O	1385	1386	.
O	1386	1388	38
O	1389	1391	to
O	1392	1393	0
O	1393	1394	.
O	1394	1396	54
O	1396	1397	;
O	1398	1401	log
O	1401	1402	-
O	1402	1406	rank
O	1406	1407	,
O	1408	1409	1
O	1409	1410	-
O	1410	1415	sided
O	1416	1417	P
O	1418	1419	<
O	1420	1421	.
O	1421	1425	0001
O	1425	1426	)
O	1426	1427	.

B-outcome	1428	1432	Bone
I-outcome	1433	1439	marker
I-outcome	1440	1446	levels
I-outcome	1447	1449	at
I-outcome	1450	1451	6
I-outcome	1452	1455	and
I-outcome	1456	1458	12
I-outcome	1459	1464	weeks
O	1465	1474	increased
O	1475	1479	with
O	1480	1490	exemestane
O	1491	1495	only
O	1495	1496	,
O	1497	1499	as
O	1500	1508	expected
O	1508	1509	,
O	1510	1513	but
O	1514	1523	decreased
O	1524	1528	with
O	1529	1532	the
O	1533	1544	combination
O	1544	1545	.

O	1546	1549	The
B-outcome	1550	1560	cumulative
I-outcome	1561	1570	incidence
I-outcome	1571	1575	rate
I-outcome	1576	1578	of
I-outcome	1579	1590	progressive
I-outcome	1591	1598	disease
I-outcome	1599	1601	in
I-outcome	1602	1606	bone
O	1607	1610	was
O	1611	1616	lower
O	1617	1619	in
O	1620	1623	the
O	1624	1635	combination
O	1636	1639	arm
O	1639	1640	.

B-outcome	1641	1645	Bone
I-outcome	1645	1646	-
I-outcome	1646	1653	related
I-outcome	1654	1661	adverse
I-outcome	1662	1668	events
O	1669	1677	occurred
O	1678	1682	with
O	1683	1690	similar
O	1691	1700	frequency
O	1701	1703	in
O	1704	1708	both
O	1709	1713	arms
O	1714	1715	(
B-iv-bin-percent	1715	1716	3
I-iv-bin-percent	1716	1717	.
I-iv-bin-percent	1717	1718	3
I-iv-bin-percent	1718	1719	%
O	1720	1731	combination
O	1732	1734	vs
B-cv-bin-percent	1735	1736	4
I-cv-bin-percent	1736	1737	.
I-cv-bin-percent	1737	1738	2
I-cv-bin-percent	1738	1739	%
O	1740	1750	exemestane
O	1751	1755	only
O	1755	1756	)
O	1756	1757	.

O	1758	1763	These
O	1764	1775	exploratory
O	1776	1784	analyses
O	1785	1792	suggest
O	1793	1797	that
O	1798	1808	everolimus
O	1809	1812	has
O	1813	1823	beneficial
O	1824	1831	effects
O	1832	1834	on
O	1835	1839	bone
O	1840	1848	turnover
O	1849	1852	and
O	1853	1864	progressive
O	1865	1872	disease
O	1873	1875	in
O	1876	1880	bone
O	1881	1883	in
O	1884	1892	patients
O	1893	1902	receiving
O	1903	1913	exemestane
O	1914	1917	for
O	1918	1925	hormone
O	1926	1934	receptor
O	1934	1935	-
O	1935	1943	positive
O	1944	1950	breast
O	1951	1957	cancer
O	1958	1969	progressing
O	1970	1976	during
O	1976	1977	/
O	1977	1982	after
O	1983	1995	nonsteroidal
O	1996	2005	aromatase
O	2006	2015	inhibitor
O	2016	2023	therapy
O	2023	2024	.
